[Immunogenicity and long-term effectiveness of the hepatitis B vaccine in newborns from HBsAg-positive mothers].
We have followed up until age 2 years 25 infants who had received the hepatitis B vaccine to prevent being infected from their mothers who were HBsAg carriers. All had developed antibodies. At 2 years of age, 24% of infants had antiHBsAg titers lower than 10 mU/ml. The geometric mean of antiHBsAg titer in those infants who had received plasma derived vaccine was 660 mU/ml and in those having received recombinant vaccine was 903 mU/ml. HBsAg was negative in all the studied samples. In two infants positive antiHBc were detected.
Torres
J M
JM
Servicio de Pediatría, Hospital Clínic i Provincial, Barcelona.
Bruguera
M
M
Fos
E
E
Mayor
A
A
Hierro
F R
FR
D002353:Carrier State / Q000635:transmission; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000517:prevention & control* / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines; D006801:Humans; D007231:Infant, Newborn; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines
Inmunogenicidad y eficacia a largo plazo de la vacuna de la hepatitis B en recién nacidos de madres portadoras de HBsAg.